SAB Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SAB Biotherapeutics's estimated annual revenue is currently $6.4M per year.
- SAB Biotherapeutics's estimated revenue per employee is $100,500
- SAB Biotherapeutics's total funding is $40.4M.
Employee Data
- SAB Biotherapeutics has 64 Employees.
- SAB Biotherapeutics grew their employee count by 7% last year.
SAB Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, Executive Chairman | Reveal Email/Phone |
2 | Chief Corporate Communications & Investor Relations Officer | Reveal Email/Phone |
3 | SVP, Research and Product Development | Reveal Email/Phone |
4 | VP, Clinical Operations | Reveal Email/Phone |
5 | Controller | Reveal Email/Phone |
6 | EVP & Chief Operating Officer | Reveal Email/Phone |
7 | Director | Reveal Email/Phone |
8 | Executive Director, Animal Management | Reveal Email/Phone |
9 | Executive Director Molecular Genetics & Immunology | Reveal Email/Phone |
10 | Senior Director Regulatory Affairs | Reveal Email/Phone |
SAB Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is SAB Biotherapeutics?
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.
keywords:N/A
$40.4M
Total Funding
64
Number of Employees
$6.4M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SAB Biotherapeutics News
That average rating earns SAB Biotherapeutics Inc an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data...
Sioux Falls-based SAB Biotherapeutics provided updates on its therapeutics for COVID-19, influenza and type 1 diabetes in reporting its...
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human...
SAB Biotherapeutics, a Sioux Falls, S.D.-based clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, closed a $14m Series B funding round. New investor, global healthcare leader Merck, known ...
SIOUX FALLS, S.D.–(BUSINESS WIRE)–January 7, 2020– SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader ...
Other Companies in Sioux Falls
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.1M | 64 | 2% | N/A |
#2 | $18.5M | 64 | 5% | N/A |
#3 | $8.2M | 65 | -10% | N/A |
#4 | $12M | 65 | -3% | N/A |
#5 | $17.2M | 66 | 8% | N/A |